Home
Science and IP
Investors
Our Team
Events
News Releases
Contact
NASDAQ: CMND
News Releases
Below are the latest News Releases for Clearmind Medicine Inc.
7
July
2026
Clearmind Reports Successful Formulation Feasibility Study Supporting Potential New Additional Route of Administration for MEAI
Read More
29
June
2026
Clearmind Medicine Advances Its Innovation with Newly Granted U.S. Patent, Enhancing Global Patent Strength
Read More
22
June
2026
Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA‑Regulated Phase I/II Trial
Read More
18
June
2026
Clearmind Medicine Granted U.S. Patent for Binge Behavior Regulators
Read More
16
June
2026
Clearmind Medicine Completes Dosing for Part A of its of FDA-Regulated Phase I/II Clinical Trial
Read More
6
June
2026
Clearmind Medicine to Feature New Insights from CMND-100 Psychedelic Clinical Trial on “Inside MEAI” Webinar
Read More
29
May
2026
Clearmind Advances Global IP Portfolio with Japanese Patent Filing for Innovative Psychedelic-Based Depression Treatment
Read More
26
May
2026
Clearmind Medicine Announces Johns Hopkins IRB Approval to Advance CMND-100 Phase I/II Clinical Trial to the Next Parts
Read More
18
May
2026
Clearmind Signs Agreement to Examine MEAI in Combination and Sequencing with Tirzepatide Against Blockbuster GLP-1 Medications
Read More
15
May
2026
Clearmind Medicine CEO Dr. Adi Zuloff-Shani named Delegate to Federal Policy Summit on Psychedelic Medicine in Washington, D.C.
Read More
12
May
2026
Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100
Read More
11
May
2026
Clearmind Medicine Announces “Inside MEAI” Webinar Featuring New Insights from CMND-100 Psychedelic Clinical Trial
Read More
5
May
2026
Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of PTSD
Read More
27
April
2026
Clearmind Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation
Read More
20
April
2026
Clearmind Welcomes President Trump’s Executive Order as Historic Catalyst for Psychedelic Innovation & Veteran Mental Health Care
Read More
Next
